Biocept (BIOC) Q4 EPS Beats Consensus, Revenues Beat (Correction)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
March 29, 2021 4:05 PM EDTQ4 features revenues of $18.5 million; 2020 revenues reach $27.5 million driven by COVID-19 testing
Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system
Conference call begins at 4:30 p.m. Eastern time today
SAN DIEGO--(BUSINESS... More
